Clinilabs and the DTRA Aim to Dramatically Increase Access for All Patient Populations in Clinical Trials and Research
June 7, 2021 – Clinilabs Drug Development Corporation joins a historic alliance of over one hundred life science and healthcare organizations that seek to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The “Decentralized Trials & Research Alliance (DTRA),” which launched December 10th, 2020, plans to unite industry stakeholders, including healthcare companies, regulators, patient groups and research organizations with a singular mission to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.
“We are excited to be joining a like-minded group of individuals and corporations who are focused on bringing clinical trials to patients and breaking down barriers that impede the development of new treatments for people with psychiatric and neurological disorders,” said Gary Zammit, Ph.D., founder and President of Clinilabs Drug Development Corporation.
“We are extremely gratified to welcome Clinilabs Drug Development Corporation, “Clinilabs,” to the ‘Decentralized Trials & Research Alliance,” said Amir Kalali, MD, founder of several collaborative life science communities, and co-convenor of DTRA. “By advancing decentralized research we can make the clinical trial process more patient-focused, increase trial efficiency, and encourage use of technologies. We are excited by Clinilabs’ commitment to embracing decentralized trials and to changing the culture that has been the rate limiter to innovation.”
Experts estimate that COVID-19 has caused a significant setback in non-pandemic clinical trials due to prospective patients’ inability or reluctance to schedule visits at physical research clinics. Decentralized approaches to conducting research facilitate participation by enabling remote visits or assessments. This promises to attract a larger and more diverse pool of clinical trial participants and may ease COVID-19-imposed difficulties for both patients and clinical investigators. Inclusion of representative patient populations in clinical trials by race, age, and geographic location has long been an operational challenge, but COVID-19 has placed us on the cusp of great change; change that will eliminate hurdles for potential trial participants.
“Now is the time to share ideas and insights that will chart the future course of clinical trials, accelerating drug development and saving lives – and by taking part in the DTRA, Clinilabs is demonstrating its leadership to drive change,” said Craig Lipset, DTRA co-convener, clinical innovation advisor, and a pioneer in decentralized trials. “We have a responsibility to advance the health of people with unmet medical needs, and by convening stakeholders from pharma companies, regulators, technology leaders and patient communities, we can remove remaining barriers to adoption and impact patients today.”
Clinilabs joins with its peer DTRA Member organizations to provide expertise to identify and address gaps and needs and advance best practices through effective education and communication. Clinilabs urges other organizations interested in taking part to visit DTRA.org.
ABOUT CLINILABS:
Clinilabs is a global, full-service contract research organization (CRO) focused exclusively on central nervous system (CNS) drug development, an area of significant unmet need. We are dedicated to bringing new therapies to patients living with mental health, neurological, and substance abuse disorders. Clinilabs offers customers a full spectrum of first-in-human to Phase 3 development services, working as a partner in their goal to speed new CNS medicines to market. For more information, visit clinilabs.com.
ABOUT DTRA:
The Decentralized Trials & Research Alliance (DTRA) was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research. It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods. Follow DTRA on Twitter and LinkedIn for more information.
# # #
For further information please contact:
Media Contact:
Jeanine Falinski
Vice President, Marketing and Communications
Clinilabs Drug Development Corporation
jfalinski@clinilabs.com
(646)438-4431